Eisbach Bio is at the forefront of precision oncology, focusing on the development of innovative therapies that target the molecular machines responsible for genome reorganization in cancer cells. Their approach centers on exploiting the unique vulnerabilities present in tumor genomes, particularly through the use of allosteric drugs that disrupt the activity of critical molecular machines such as nucleosome remodeling enzymes and DNA-dependent nuclear helicases. By targeting these specific proteins, Eisbach aims to induce synthetic lethality, a concept that allows for the selective targeting of cancer cells while sparing normal cells. This strategy is particularly relevant in cancers with deficiencies in DNA repair pathways, where the inhibition of these molecular machines can significantly enhance the efficacy of existing treatments, such as PARP inhibitors.

The company's proprietary ALLOS platform plays a crucial role in their drug discovery process, enabling the systematic identification and targeting of the regulatory mechanisms that control the activity of cancer-driving molecular machines. Eisbach's lead candidate, EIS-12656, is a first-in-class allosteric inhibitor of the chromatin remodeling enzyme ALC1, which is implicated in DNA damage repair and genome reorganization. By disrupting ALC1's function, Eisbach aims to halt tumor growth and improve treatment outcomes for patients with homologous recombination deficient (HRD) cancers. This innovative approach not only seeks to provide new therapeutic options but also aims to minimize side effects compared to traditional cancer therapies, thereby enhancing patient safety and treatment efficacy.

Germany

Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes.
Eisbach will beat cancer at its own game.

Eisbach Bio

Company Details